A human monoclonal antibody against HBsAg for the prevention and treatment of chronic HBV and HDV infection.

ABSTRACT:

Background & aims

Elimination of chronic HBV/HDV infection remains a major global health challenge. Targeting excessive hepatitis B surface antigen (HBsAg) release may provide an interesting window of opportunity to break immune tolerance and to achieve a functional cure using additional antivirals.

Methods

We evaluated a HBsAg-specific human monoclonal antibody, as part of either a prophylactic or therapeutic strategy, against HBV/HDV infection in cell culture models and in human-liver chimeric mice. To assess prophylactic efficacy, mice were passively immunized prior to infection with HBV or HBV/HDV (coinfection and superinfection setting). Therapeutic efficacy was assessed in HBV and HBV/HDV-coinfected mice receiving 4 weeks of treatment. Viral parameters (HBV DNA, HDV RN

SUBMITTER: Burm R 

PROVIDER: S-EPMC9898450 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature